Wall Street Zen cut shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Free Report) from a hold rating to a sell rating in a research report sent to investors on Monday,Wall Street Zen reports.
A number of other equities analysts have also weighed in on the stock. Jefferies Financial Group started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They issued a “buy” rating and a $50.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Guggenheim began coverage on Damora Therapeutics, Inc. Common Stock in a research note on Friday, November 6th. They issued a “buy” rating and a $59.00 target price for the company. Finally, TD Cowen upgraded Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, August 24th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $46.38.
View Our Latest Research Report on Damora Therapeutics, Inc. Common Stock
Damora Therapeutics, Inc. Common Stock Price Performance
Shares of NASDAQ DMRA opened at $22.50 on Monday. The firm’s 50-day moving average is $22.04 and its two-hundred day moving average is $25.60. The company has a market capitalization of $1.39 billion, a PE ratio of -15.96 and a beta of 1.52. Damora Therapeutics, Inc. Common Stock has a 12-month low of $15.76 and a 12-month high of $38.33.
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.12. On average, analysts forecast that Damora Therapeutics, Inc. Common Stock will post -2.09 EPS for the current fiscal year.
Insider Buying and Selling
In other news, CEO Jennifer Jarrett acquired 12,500 shares of the business’s stock in a transaction on Friday, September 25th. The shares were purchased at an average price of $20.23 per share, for a total transaction of $252,875.00. Following the acquisition, the chief executive officer directly owned 512,500 shares of the company’s stock, valued at $10,367,875. This represents a 2.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.40% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock
Hedge funds have recently bought and sold shares of the business. Braidwell LP acquired a new stake in Damora Therapeutics, Inc. Common Stock in the second quarter valued at $42,146,000. Seven Fleet Capital Management LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter worth about $7,398,000. Bellevue Group AG increased its position in shares of Damora Therapeutics, Inc. Common Stock by 18.6% in the 3rd quarter. Bellevue Group AG now owns 1,919,383 shares of the company’s stock worth $40,844,000 after purchasing an additional 300,537 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $303,000. Finally, Arizona State Retirement System acquired a new position in Damora Therapeutics, Inc. Common Stock in the second quarter worth about $260,000. Institutional investors and hedge funds own 14.20% of the company’s stock.
Damora Therapeutics, Inc. Common Stock Company Profile
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Further Reading
- Five stocks we like better than Damora Therapeutics, Inc. Common Stock
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Damora Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Damora Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
